查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2019265

全球系统性肥大细胞疾病治疗市场：依治疗方法、疾病亚型、给药途径、药物类别及地区进行分析－市场规模、产业趋势、机会分析及2026年至2035年预测

Global Systemic Mastocytosis Treatment Market: Analysis By Treatment Approach, Disease Subtype, Route of Administration, Drug Class, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计未来十年，全球系统性肥大细胞增生症 (SM) 治疗市场将保持稳定持续成长，这主要得益于疾病认知度的提高和治疗方法的不断创新。该市场预计在 2025 年达到约 5.6578 亿美元，并预计在 2035 年达到约 13.3756 亿美元。在 2026 年至 2035 年的预测期内，该市场将以约 9% 的复合年增长率 (CAGR) 成长，展现出强劲的上升趋势，而这一趋势的驱动力主要来自多种临床和商业性因素。

推动这一增长的主要因素是标靶治疗的持续进步，尤其是蛋白酪氨酸激酶抑制剂（TKIs）。这些药物彻底改变了进行进行性系统性肥大细胞增生症患者的治疗模式。 TKIs旨在特异性抑制KIT突变等分子驱动因素，与传统治疗方法相比，能够更精准、更有效地控制疾病。随着研究的深入和更新、更具选择性的TKIs的问世，晚期患者有望受益于更佳的治疗效果和更广泛的治疗选择。

显着的市场趋势

系统性肥大细胞增生症 (SM) 的治疗市场高度集中，少数几家主要企业占据了大部分市场份额。其中，Blueprint Medicines 公司凭藉其在标靶治疗的创新和强大的商业性实力，在市场中占据主导地位。该公司的领先地位既体现在其对精准医疗的早期投入，也体现在其成功开发出直接针对疾病分子驱动因素的治疗方法。

儘管占据主导地位，但多家主要竞争对手正积极争夺市场份额，试图重塑竞争格局。 Cogent Biosciences、诺华、AB Science 和 Decifera Pharmaceuticals 等公司正大力投资研发，以期将新型或改良治疗方法推向市场。尤其是诺华，凭藉其传统治疗方法“lydapt”，在面临来自更新、更具选择性药物的竞争日益激烈的情况下，仍然保持着市场地位。 「lydapt」在特定患者群体中仍然发挥着重要作用。

2026年，SM治疗市场的竞争格局将如同高风险的西洋棋比赛，各公司将投入大量资金以求获得竞争优势。这不仅包括对临床试验和药物研发的投资，还包括监管策略、市场进入以及与医生合作等方面的努力。任何进展，例如新疗法的推出、适应症的拓展或现有製剂的改进，都可能显着改变市场格局。

  • 主要成长要素
  • 系统性肥大细胞增多症 (SM) 治疗市场的成长受到更广泛的人口趋势的显着影响，尤其是老年人口的快速成长。随着预期寿命的延长和医疗保健体系的改善，老年人口的比例持续上升，慢性病和罕见疾病患者群体不断扩大。预计到 2050 年，美国老年人口将达到约 8,200 万，这反映了显着的人口结构变化，预计将导致对医疗保健服务和专科治疗的需求增加。
  • 新机会的趋势
  • 系统性肥大细胞增生症 (SM) 治疗领域的一个重大新趋势是从骨髓切片检查等侵入性诊断方法转向高灵敏度的周边血液检测，例如液滴数位 PCR (ddPCR)。这项转变显着改善了患者识别流程，使诊断更加便捷、减轻了负担，并被更广泛地接受。虽然传统的骨髓切片检查准确，但它属于侵入性检查，通常伴随疼痛，需要在专门的临床环境中进行，这可能导致患者犹豫不决，从而延误诊断。
  • 优化障碍
  • 儘管系统性肥大细胞增生症 (SM) 的治疗市场正经历强劲成长，但仍存在一些重大限制因素阻碍其广泛应用。其中最主要的挑战之一是治疗带来的沉重经济负担，尤其是蛋白酪氨酸激酶抑制剂 (TKI) 等先进治疗方法。这些药物每年的费用可能高达 44.5 万美元左右，对患者、医疗系统和保险公司而言都是一笔不小的开销。即使在医保报销系统完善的地区，如此高昂的费用也会限制患者获得治疗的机会，延误治疗启动，甚至导致治疗中断，尤其对于那些保险覆盖不足的患者而言更是如此。

目录

第一章执行摘要：系统性肥大细胞疾病治疗的全球市场

第二章：报告概述

  • 研究框架
    • 研究目标
    • 市场的定义
    • 市场区隔
  • 调查方法
    • 市场规模估算
    • 定性研究
    • 量化研究
    • 按地区分類的主要调查受访者组成
    • 数据检验
    • 本研究的前提

第三章：系统性肥大细胞疾病治疗全球市场概览

  • 产业价值链分析
    • 原料
    • 药物发现与研究
    • 药物研发和临床试验
    • 製造业
    • 分销管道
    • 医疗保健专业人员
    • 最终用户
  • 产业展望
    • 系统性肥大细胞增生症的疾病概述和流行病学
    • 目前治疗状况（标靶治疗与对症治疗）
    • 精准医疗在罕见血液疾病中的作用
    • 开发平臺和临床开发方案
    • 用于诊断和治疗罕见疾病的医疗基础设施
    • 孤儿药认定方面的监理现况与趋势
  • PESTLE分析
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场成长及前景
    • 市场获利估算与预测（2020-2035）
  • 市场吸引力分析
    • 药物类别
  • 可执行的见解（分析师建议）

第四章：竞争对手仪錶板

  • 市场集中度
  • 企业市场占有率分析（以金额为准，2025 年）
  • 竞争格局分析与基准测试

第五章：系统性肥大细胞疾病治疗的全球市场分析

  • 市场动态和趋势
    • 成长要素
    • 抑制因子
    • 机会
    • 主要趋势
  • 市场规模及预测（2020-2035）
    • 药物类别
      • 关键见解
        • 多激酶抑制剂
        • 抗组织胺药
        • KIT抑制剂
        • 肥大细胞稳定剂
        • 皮质类固醇
        • 免疫调节药物
        • 其他的
    • 依疾病亚型
      • 关键见解
        • 低度系统性肥大细胞增生症
        • 隐匿性系统性肥大细胞增生症
        • 高恶性度系统性肥大细胞增生症
        • 系统性肥大细胞增多症伴随造血系统恶性肿瘤
        • 肥大细胞白血病
    • 依疾病亚型
      • 关键见解
        • 标靶治疗
        • 症状治疗方法
        • 细胞减重疗法
        • 联合治疗
    • 透过行政途径
      • 关键见解
        • 口服
        • 注射药物
        • 静脉注射
    • 按地区
      • 关键见解
        • 北美洲
          • 我们
          • 加拿大
          • 墨西哥
        • 欧洲
          • 西欧
            • 英国
            • 德国
            • 法国
            • 义大利
            • 西班牙
            • 其他西欧国家
          • 东欧
            • 波兰
            • 俄罗斯
            • 其他东欧国家
        • 亚太地区
          • 中国
          • 印度
          • 日本
          • 韩国
          • 澳洲和纽西兰
          • ASEAN
            • 印尼
            • 马来西亚
            • 泰国
            • 新加坡
            • 其他东协国家
          • 其他亚太地区
        • 中东和非洲
          • 阿拉伯聯合大公国
          • 沙乌地阿拉伯
          • 南非
          • 其他中东和非洲
        • 南美洲
          • 阿根廷
          • 巴西
          • 南美洲其他地区

第六章：北美系统性肥大细胞疾病治疗市场分析

第七章：欧洲系统性乳房疾病治疗市场分析

第八章：亚太地区系统性肥大细胞增多症治疗市场分析

第九章：中东和非洲系统性肥大细胞疾病治疗市场分析

第十章：南美洲系统性乳房疾病治疗市场分析

第十一章：公司简介

  • Sanofi SA
  • AdvaCare Pharma
  • Cogent Biosciences, Inc.
  • Dr Reddys Laboratories Ltd.
  • AB Science SA
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Other Prominent Players

第十二章附录

简介目录
Product Code: AA03261743

The global systemic mastocytosis (SM) treatment market is poised for steady and sustained growth over the coming decade, reflecting both increasing disease recognition and ongoing therapeutic innovation. The market is estimated to be valued at approximately USD 565.78 million in 2025 and is projected to reach around USD 1,337.56 million by 2035. This expansion represents a compound annual growth rate (CAGR) of about 9% during the forecast period from 2026 to 2035, indicating a robust upward trajectory driven by multiple clinical and commercial factors.

A key contributor to this growth is the continued advancement of targeted therapies, particularly tyrosine kinase inhibitors (TKIs), which have transformed the treatment landscape for patients with advanced systemic mastocytosis. These therapies are designed to specifically inhibit molecular drivers such as KIT mutations, enabling more precise and effective disease control compared to traditional treatment approaches. As research progresses and newer, more selective TKIs are introduced, patients with advanced forms of the disease are expected to benefit from improved outcomes and expanded treatment options.

Noteworthy Market Developments

The systemic mastocytosis (SM) treatment market is characterized by a high level of consolidation, with a small number of key players controlling a significant share of the landscape. Among these, Blueprint Medicines stands out as the dominant force, largely due to its focused innovation in targeted therapies and its strong commercial presence. The company's leadership position reflects both early investment in precision medicine approaches and successful development of treatments that directly address the molecular drivers of the disease.

Despite this dominance, several major challengers are actively competing to capture market share and reshape the competitive dynamics. Companies such as Cogent Biosciences, Novartis, AB Science, and Deciphera Pharmaceuticals are all investing heavily in research and development to bring new or improved therapies to market. In particular, Novartis continues to defend its established position with Rydapt. This is a legacy treatment that still plays a role in certain patient segments despite increasing competition from newer, more selective agents.

By 2026, the competitive landscape of the SM treatment market can be likened to a high-stakes chess match, where each company strategically deploys substantial financial resources to gain an advantage. This includes not only investment in clinical trials and drug development but also efforts in regulatory strategy, market access, and physician engagement. Every move-whether launching a new therapy, expanding indications, or improving existing formulations-can significantly alter market positioning.

  • Core Growth Drivers
  • The growth of the systemic mastocytosis (SM) treatment market is strongly influenced by broader demographic trends, particularly the rapid expansion of the aging population. As life expectancy increases and healthcare systems improve, the proportion of older individuals continues to rise, creating a larger pool of patients susceptible to chronic and rare diseases. In the United States, the geriatric population is projected to reach approximately 82 million by 2050, reflecting a substantial demographic shift that is expected to place increased demand on healthcare services and specialized treatments.
  • Emerging Opportunity Trends
  • A major emerging trend in the systemic mastocytosis (SM) treatment landscape has been the shift from invasive diagnostic procedures, such as bone marrow biopsies, to highly sensitive peripheral blood testing methods like droplet digital PCR (ddPCR). This transition has significantly improved the process of identifying patients with the disease, making diagnosis more accessible, less burdensome, and more widely accepted. Traditional bone marrow biopsies, while accurate, are invasive, often painful, and require specialized clinical settings, which can discourage patients from undergoing testing and delay diagnosis.
  • Barriers to Optimization
  • Despite the strong growth of the systemic mastocytosis (SM) treatment market, several significant restraints continue to limit its broader adoption. One of the most critical challenges is the severe financial burden associated with treatment, particularly with advanced therapies such as tyrosine kinase inhibitors (TKIs). These medications can cost approximately $445,000 per year, creating substantial economic strain for patients, healthcare systems, and insurers. Even in regions with strong reimbursement frameworks, such high costs can restrict accessibility, delay treatment initiation, or lead to discontinuation, especially for patients without adequate insurance coverage.

Detailed Market Segmentation

By drug class, Tyrosine Kinase Inhibitors (TKIs) hold a dominant position in the systemic mastocytosis (SM) treatment market, accounting for approximately 40% of the total share. This leadership is largely driven by their effectiveness in targeting the underlying molecular mechanisms of the disease, particularly mutations that drive abnormal mast cell growth and activation. As treatment approaches increasingly shift toward precision medicine, TKIs have become a cornerstone therapy due to their ability to inhibit disease-causing pathways.

By route of administration, oral therapies dominate the systemic mastocytosis (SM) treatment market, accounting for approximately 65% of the total share. This strong preference is closely linked to the chronic and lifelong nature of the disease, which requires continuous management rather than short-term intervention. Patients and healthcare providers generally favor treatment options that can be easily integrated into daily life, making oral medications a practical and convenient choice compared to hospital-based alternatives such as intravenous therapies.

By treatment approach, the targeted therapy segment represents the leading treatment approach in the systemic mastocytosis (SM) treatment market, accounting for approximately 41% of the total market share. This strong position is largely attributed to the growing shift toward precision medicine, where therapies are specifically designed to address the underlying molecular mechanisms of the disease rather than just managing symptoms. As healthcare systems increasingly prioritize personalized treatment strategies, targeted therapies have gained widespread acceptance among clinicians and researchers.

Segment Breakdown

By Drug Class

  • Multikinase inhibitors
  • Antihistamines
  • KIT inhibitors
  • Mast cell stabilizers
  • Corticosteroids
  • Immunomodulators
  • Others

By Disease Subtype

  • Indolent systemic mastocytosis
  • Smoldering systemic mastocytosis
  • Aggressive systemic mastocytosis
  • Systemic mastocytosis with associated hematologic neoplasm
  • Mast cell leukemia

By Treatment Approach

  • Targeted therapy
  • Symptomatic management therapy
  • Cytoreductive therapy
  • Combination therapy

By Route of Administration

  • Oral
  • Injectable
  • Intravenous

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a leading position in the systemic mastocytosis (SM) treatment market, accounting for 42.16% of the global share. This dominance reflects the region's well-established healthcare infrastructure, strong research ecosystem, and high level of awareness among clinicians and patients. Within North America, the United States plays a particularly significant role, contributing approximately 75% of the region's total market value.
  • A key factor supporting this growth is the impact of the FDA's Orphan Drug Act, which provides powerful incentives for companies developing therapies for rare conditions such as systemic mastocytosis. These incentives include seven years of market exclusivity upon approval, as well as tax credits and other financial benefits that reduce the cost burden of research and development. As a result, pharmaceutical companies are more willing to invest in innovative treatments, accelerating the pace of drug discovery and commercialization in this niche therapeutic area.
  • In addition to regulatory support, North America benefits from widespread adoption of advanced diagnostic technologies. Next-Generation Sequencing (NGS), now used in approximately 90% of oncology centers, has significantly improved the accuracy and efficiency of detecting genetic mutations associated with systemic mastocytosis, particularly mutations in the KIT gene. This high level of diagnostic precision enables earlier and more reliable identification of the disease, which in turn supports timely intervention and better patient outcomes.

Leading Market Participants

  • Sanofi SA
  • AdvaCare Pharma
  • Cogent Biosciences, Inc.
  • Dr Reddy's Laboratories Ltd.
  • AB Science SA
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Systemic Mastocytosis Treatment Market

Chapter 2. Report Description

  • 2.1. Research Framework
    • 2.1.1. Research Objective
    • 2.1.2. Market Definitions
    • 2.1.3. Market Segmentation
  • 2.2. Research Methodology
    • 2.2.1. Market Size Estimation
    • 2.2.2. Qualitative Research
      • 2.2.2.1. Primary & Secondary Sources
    • 2.2.3. Quantitative Research
      • 2.2.3.1. Primary & Secondary Sources
    • 2.2.4. Breakdown of Primary Research Respondents, By Region
    • 2.2.5. Data Triangulation
    • 2.2.6. Assumption for Study

Chapter 3. Global Systemic Mastocytosis Treatment Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Materials
    • 3.1.2. Drug Discovery & Research
    • 3.1.3. Drug Development & Clinical Trials
    • 3.1.4. Manufacturing
    • 3.1.5. Distribution Channels
    • 3.1.6. Healthcare Providers
    • 3.1.7. End User
  • 3.2. Industry Outlook
    • 3.2.1. Disease Landscape & Epidemiology of Systemic Mastocytosis
    • 3.2.2. Treatment Landscape (Targeted Therapy vs Symptomatic Management)
    • 3.2.3. Role of Precision Medicine in Rare Hematologic Disorders
    • 3.2.4. Drug Pipeline & Clinical Development Scenario
    • 3.2.5. Healthcare Infrastructure for Rare Disease Diagnosis & Treatment
    • 3.2.6. Regulatory & Orphan Drug Designation Landscape
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. By Drug Class
  • 3.7. Actionable Insights (Analyst's Recommendations)

Chapter 4. Competition Dashboard

  • 4.1. Market Concentration Rate
  • 4.2. Company Market Share Analysis (Value %), 2025
  • 4.3. Competitor Mapping & Benchmarking

Chapter 5. Global Systemic Mastocytosis Treatment Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
      • 5.1.1.1. Increasing Adoption of Targeted Therapies for Treatment of Systemic Mastocytosis
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Drug Class
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Multikinase Inhibitors
        • 5.2.1.1.2. Antihistamines
        • 5.2.1.1.3. KIT Inhibitors
        • 5.2.1.1.4. Mast Cell Stabilizers
        • 5.2.1.1.5. Corticosteroids
        • 5.2.1.1.6. Immunomodulators
        • 5.2.1.1.7. Others
    • 5.2.2. By Disease Subtype
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Indolent Systemic Mastocytosis
        • 5.2.2.1.2. Smoldering Systemic Mastocytosis
        • 5.2.2.1.3. Aggressive Systemic Mastocytosis
        • 5.2.2.1.4. Systemic Mastocytosis with Associated Hematologic Neoplasm
        • 5.2.2.1.5. Mast Cell Leukemia
    • 5.2.3. By Treatment Approach
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Targeted Therapy
        • 5.2.3.1.2. Symptomatic Management Therapy
        • 5.2.3.1.3. Cytoreductive Therapy
        • 5.2.3.1.4. Combination Therapy
    • 5.2.4. By Route of Administration
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Oral
        • 5.2.4.1.2. Injectable
        • 5.2.4.1.3. Intravenous
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
            • 5.2.5.1.3.6.1. Indonesia
            • 5.2.5.1.3.6.2. Malaysia
            • 5.2.5.1.3.6.3. Thailand
            • 5.2.5.1.3.6.4. Singapore
            • 5.2.5.1.3.6.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Systemic Mastocytosis Treatment Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. By Drug Class
    • 6.2.2. By Disease Subtype
    • 6.2.3. By Treatment Approach
    • 6.2.4. By Route of Administration
    • 6.2.5. By Country

Chapter 7. Europe Systemic Mastocytosis Treatment Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. By Drug Class
    • 7.2.2. By Disease Subtype
    • 7.2.3. By Treatment Approach
    • 7.2.4. By Route of Administration
    • 7.2.5. By Country

Chapter 8. Asia Pacific Systemic Mastocytosis Treatment Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. By Drug Class
    • 8.2.2. By Disease Subtype
    • 8.2.3. By Treatment Approach
    • 8.2.4. By Route of Administration
    • 8.2.5. By Country

Chapter 9. Middle East & Africa Systemic Mastocytosis Treatment Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. By Drug Class
    • 9.2.2. By Disease Subtype
    • 9.2.3. By Treatment Approach
    • 9.2.4. By Route of Administration
    • 9.2.5. By Country

Chapter 10. South America Systemic Mastocytosis Treatment Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. By Drug Class
    • 10.2.2. By Disease Subtype
    • 10.2.3. By Treatment Approach
    • 10.2.4. By Route of Administration
    • 10.2.5. By Country

Chapter 11. Company Profile (Company Overview, Company Timeline, Organization Structure, Key Product landscape, Financial Matrix, Key Customers/Sectors, Key Competitors, SWOT Analysis, Contact Address, and Business Strategy Outlook)

  • 11.1. Sanofi SA
  • 11.2. AdvaCare Pharma
  • 11.3. Cogent Biosciences, Inc.
  • 11.4. Dr Reddys Laboratories Ltd.
  • 11.5. AB Science SA
  • 11.6. Glenmark Pharmaceuticals Ltd.
  • 11.7. Lupin Ltd.
  • 11.8. Pfizer Inc.
  • 11.9. Novartis AG
  • 11.10. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators